List of Embeda drug patents
Embeda is owned by Alpharma Pharms.
Embeda contains Morphine Sulfate; Naltrexone Hydrochloride.
Embeda has a total of 9 drug patents out of which 0 drug patents have expired.
Embeda was authorised for market use on 13 August, 2009.
Embeda is available in capsule, extended release;oral dosage forms.
Embeda can be used as management of pain severe enough to require daily, around-the-clock, long term opioid treatement by orally administering an intact composition as claimed., management of pain severe enough to require daily, around-the-clock, long term opioid treatment by orally administering a plurality of composite subunits as claimed, treatment of moderate to severe chronic pain by administering an intact composition as claimed.
The generics of Embeda are possible to be released after 07 November, 2029.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8685443 | ALPHARMA PHARMS | Sequestering subunit and related compositions and methods |
Jul, 2025
(2 years from now) | |
| US8685444 | ALPHARMA PHARMS | Sequestering subunit and related compositions and methods |
Jul, 2025
(2 years from now) | |
| US8846104 | ALPHARMA PHARMS | Pharmaceutical compositions for the deterrence and/or prevention of abuse |
Jun, 2027
(4 years from now) | |
| US8877247 | ALPHARMA PHARMS | Abuse-deterrent multi-layer pharmaceutical composition comprising an opioid antagonist and an opioid agonist |
Jun, 2027
(4 years from now) | |
| US7682633 | ALPHARMA PHARMS | Pharmaceutical composition |
Jun, 2027
(4 years from now) | |
| US7682634 | ALPHARMA PHARMS | Pharmaceutical compositions |
Jun, 2027
(4 years from now) | |
| US8158156 | ALPHARMA PHARMS | Abuse-deterrent multi-layer pharmaceutical composition comprising an opioid antagonist and an opioid agonist |
Jun, 2027
(4 years from now) | |
| US7815934 | ALPHARMA PHARMS | Sequestering subunit and related compositions and methods |
Dec, 2027
(4 years from now) | |
| US8623418 | ALPHARMA PHARMS | Pharmaceutical composition |
Nov, 2029
(6 years from now) | |
Drugs and Companies using MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE ingredient
Market Authorisation Date: 13 August, 2009
Treatment: Management of pain severe enough to require daily, around-the-clock, long term opioid treatment by orally administering a plurality of composite subunits as claimed; Management of pain severe enough to require daily, around-the-clock, long term opioid treatement by orally administering an intact composition as claimed.; Treatment of moderate to severe chronic pain by administering an intact composition as claimed
Dosage: CAPSULE, EXTENDED RELEASE;ORAL
EMBEDA family patents
23
United States
9
European Union
7
Australia
5
Portugal
5
Spain
5
Cyprus
5
Slovenia
5
Denmark
4
Hungary
4
Poland
3
Korea, Republic of
3
Canada
2
China
2
Israel
1
Russia
1
Brazil
1
New Zealand
1
Norway
1
Austria
1
Mexico
1
Hong Kong
1
South Africa
1
Japan
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic